Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study [Hematologic Malignancy]
Conclusion
This phase II study demonstrates that BeGEV is an effective salvage regimen able to induce CR in a high proportion of patients with relapsed or refractory HL before ASCT. These data provide a strong rationale for further development of the BeGEV regimen.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Santoro, Mazza, Pulsoni, Re, Bonfichi, Zilioli, Salvi, Merli, Anastasia, Luminari, Annechini, Gotti, Peli, Liberati, Di Renzo, Castagna, Giordano, Carlo-Stella Tags: Leukemia Hematologic Malignancy Source Type: research
More News: Bone Graft | Cancer & Oncology | Chemotherapy | Hematology | Leukemia | Lymphoma | Stem Cell Therapy | Stem Cells | Study | Thrombocytopenia | Toxicology | Transplants | Treanda